Halozyme Therapeutics (HALO) Stock Price, News & Analysis

Company Overview

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $60.44 to $61.48
• 50-Day Range: $47.74 to $61.45
• 52-Week Range: $37.73 to $65.53
• Volume: 992,126 shs
• Average Volume: 1.31 million shs
• Market Capitalization: $7.52 billion
• P/E Ratio: 17.80
• Dividend Yield: N/A
• Price Target: $62.78
• Consensus Rating: Moderate Buy

Halozyme Therapeutics Stock Analysis - MarketRank™

Halozyme Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 177th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Halozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Halozyme Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 31.50%

Earnings Growth

Earnings for Halozyme Therapeutics are expected to grow by 31.50% in the coming year, from $4.73 to $6.22 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Halozyme Therapeutics is 17.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.31.

Price to Earnings Ratio vs. Sector

The P/E ratio of Halozyme Therapeutics is 17.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.52.

Price to Earnings Growth Ratio

Halozyme Therapeutics has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Halozyme Therapeutics has a P/B Ratio of 20.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.01% of the float of Halozyme Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Halozyme Therapeutics has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Halozyme Therapeutics has recently increased by 5.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Halozyme Therapeutics does not currently pay a dividend.

Dividend Growth

Halozyme Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

8.01% of the float of Halozyme Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Halozyme Therapeutics has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Halozyme Therapeutics has recently increased by 5.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.87

News Sentiment

Halozyme Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Halozyme Therapeutics this week, compared to 9 articles on an average week.

Search Interest

11 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.

MarketBeat Follows

5 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,754,451.00 in company stock.

Percentage Held by Insiders

Only 2.40% of the stock of Halozyme Therapeutics is held by insiders.

Percentage Held by Institutions

97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HALO Stock Analysis - Frequently Asked Questions

How have HALO shares performed this year?

Halozyme Therapeutics' stock was trading at $47.81 at the beginning of 2025. Since then, HALO stock has increased by 27.7% and is now trading at $61.06.
View the best growth stocks for 2025 here.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, February, 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The biopharmaceutical company earned $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 157.78% and a net margin of 43.74%.

Does Halozyme Therapeutics have any subsidiaries?

Halozyme Therapeutics subsidiaries include these companies: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' top institutional investors include Vanguard Group Inc. (10.44%), Snyder Capital Management L P (3.28%), Alliancebernstein L.P. (2.41%) and Geode Capital Management LLC (2.41%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Jeffrey William Henderson, James M Daly and Nicole Labrosse.
View institutional ownership trends.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 2/18/2025
• Today: 3/14/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HALO
• CIK: 1159036
• Web: www.halozyme.com
• Phone: 858-794-8889
• Fax: 858-704-8311
• Employees: 390
• Year Founded: 1998

Price Target and Rating

• Average Stock Price Target: $62.78
• High Stock Price Target: $75.00
• Low Stock Price Target: $49.00
• Potential Upside/Downside: +2.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $3.43
• Trailing P/E Ratio: 17.80
• Forward P/E Ratio: 12.91
• P/E Growth: 0.42
• Net Income: $281.59 million
• Net Margins: 43.74%
• Pretax Margin: 54.87%
• Return on Equity: 157.78%
• Return on Assets: 25.34%

Debt

• Debt-to-Equity Ratio: 4.14
• Current Ratio: 7.80
• Quick Ratio: 9.15

Sales & Book Value

• Annual Sales: $1.02 billion
• Price / Sales: 7.41
• Cash Flow: $4.94 per share
• Price / Cash Flow: 12.35
• Book Value: $2.95 per share
• Price / Book: 20.70

Miscellaneous

• Outstanding Shares: 123,153,000
• Free Float: 120,197,000
• Market Cap: $7.52 billion
• Optionable: Optionable
• Beta: 1.32